H
Hinova Pharma
Hinova Pharma is a pharmaceutical company
About Hinova Pharma
Hinova Pharma is an international, clinical-stage pharmaceutical company dedicated to developing innovative therapeutics for cancer and metabolic syndromes. The company leverages advanced technologies such as PROTAC (Proteolysis Targeting Chimeras) and deuteration to create best-in-class and first-in-class drugs. Hinova Pharma operates in the global pharmaceutical market, serving patients who require effective, safe, and affordable medications for serious health conditions. The business model is centered around research and development (R&D), with four core R&D platforms: PROTAC Platform, Deuteration Platform, Novel Target Discovery and Validation Platform, and Translational Medical Technology Platform. These platforms enable the company to discover, develop, and bring to market novel therapeutics. Hinova Pharma generates revenue through the development and commercialization of its proprietary drugs, as well as through strategic collaborations and partnerships. The company has submitted over 200 PCT and national patents, with more than 90 patents granted globally, including in the US, EU, and Japan. Hinova Pharma's flagship product, HC 1119, a deuterated compound of enzalutamide, is currently undergoing Phase III clinical trials and has shown potential for higher safety and efficacy.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Oct 2020 | $147M | $588M | Tigermed · CICC · Sealand Innovation · Haurong Rongde Asset Management | — |
| SERIES BOther financing | Jan 2020 | $32M | $128M | GF Xinde Investment | — |
Growth signals
Latest recorded traffic for Hinova Pharma is 1K monthly website visits, up 66.7% over the last three months. Hinova Pharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Haisco
Shanghai Fosun Pharmaceutical- HCHermed Capital
Prosper Capital- GIGF Xinde Investment
Series B and later11 investors entered at this stage
Tigermed
CICC- SISealand Innovation
- HMHaurong Rongde Asset Management
DNV capital
Hangzhou Tigermed- SHShenzhen Investment Holdings
Infinity Group
CCB International- HAHongtai Aplus
- FFFounder H Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hinova Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hinova Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.